Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention

doi:10.3748/wjg.v25.i26.3299

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12688)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

835

WORD

426

HTML

6167

Figures (1-1)

600

Tables (1-1)

531

Sum=8559

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

504

Download

1066

Sum=1570

Publishing Process of This Article

Item

Count

Browse

972

Download

1587

Sum=2559

Jul 14, 2019 (publication date) through Nov 9, 2025

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastroenterol. Jul 14, 2019; 25(26): 3299-3312
Published online Jul 14, 2019. doi: 10.3748/wjg.v25.i26.3299

Table 1 Incidence of hepatitis B virus replication in hemo-lymphoproliferative diseases and related management, according to hepatitis B virus markers and type of immunosuppressive regimens

Drug classes	Drugs	Incidence of HBVr in the absence of HBV prophylaxis		Management of HBVr
Drug classes	Drugs	HBsAg-positive (%)	HBsAg-negative/HBcAb-positive (%)	HBsAg- positive	HBsAg-negative/HBcAb-positive
Monoclonal antibody	Rituximab	High: 30-60	High: > 10	ETV	LMV
	Ofatumumab			TDF
	Obinutuzumab			TAF
	Alemtuzumab			TAF
Anthracycline chemotherapy	Doxorubicin	High: 15-30	Moderate: 1-10	ETV	LMV
	Epirubicin Daunorubicin			TDF
	Epirubicin Daunorubicin			TAF
Tyrosine kinase inhibitors	Imatinib, Nilotinib	Moderate: 1-10	Moderate: 1-10	ETV	LMV
	Imatinib, Nilotinib			TDF
	Dasatinib
	Bosutinib
	Ponatinib			TAF
Proteasome inhibitors	Bortezomib	Moderate: 1-10	Moderate: 1-10	ETV	LMV
	Carfilzomib			TDF
	Ixazomib			TAF
Inhibitors of cytokine	Mogamulizumab	Moderate: 1-10	Moderate: 1-10	ETV	LMV
				TDF
				TAF
Corticosteroids	High/moderate dose of prednisone	High: > 10	Moderate: 1-10	ETV	LMV
				TDF
				TAF

HBV: Hepatitis B virus; HBVr: Hepatitis B virus replication; HbsAg: Hepatitis B surface antigen; HbcAb: Hepatitis B core antibodies; ETV: Entecavir; TDF: Tenofovir; TAF: Tenofovir alafenamide; LMV: Lamivudine.

Full Size Table

Citation: Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol 2019; 25(26): 3299-3312
URL: https://www.wjgnet.com/1007-9327/full/v25/i26/3299.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i26.3299